RDIF and partners invest in Alium pharmaceutical holding

A consortium of investors, including the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), the Russia-China Investment Fund (RCIF, established by RDIF and China Investment Corporation), and leading Middle Eastern funds, have announced a 28% stake in Alium pharmaceutical holding, the corporate web page reported.

Alium holding is created by a merger between the pharmaceutical companies Obolenskoe and Binnopharm. Following the merger, Alium is among the top-10 Russian pharmaceutical companies in the sector, with a diversified portfolio of over 200 drugs. The production capacity of the merged company is supplied by four pharmaceutical production units in Moscow and the Moscow region. 

Previous ArticleNext Article